A fixed-dose combination (FDC) of an antispasmodic (Drotaverine) and a non-steroidal anti-inflammatory drug (NSAID) of the fenamate class (Mefenamic Acid). It is primarily indicated for the symptomatic relief of pain associated with smooth muscle spasms, particularly in dysmenorrhea and abdominal colics. Drotaverine relieves spasm, while Mefenamic Acid reduces pain and inflammation. This combination is widely used in India for gynecological and gastrointestinal conditions.
Adult: One tablet (Drotaverine 80mg + Mefenamic Acid 250mg) every 6-8 hours as needed for pain. Should be taken with or after food. Maximum: 3 tablets in 24 hours.
Note: Take with a full glass of water, preferably with food or milk to minimize gastrointestinal upset. Do not crush or chew. Swallow whole. Do not lie down for at least 10 minutes after taking the tablet.
The combination exerts a dual action: Drotaverine causes direct relaxation of smooth muscle, while Mefenamic Acid inhibits prostaglandin synthesis, providing analgesic, anti-inflammatory, and antipyretic effects. This synergistically relieves colicky pain arising from smooth muscle spasm in the uterus, gastrointestinal tract, and biliary system.
Pregnancy: Pregnancy Category C (first and second trimester) and Category D (third trimester). Avoid in third trimester due to risk of premature closure of ductus arteriosus, delayed labor, and potential renal dysfunction in the newborn. Use in first and second trimesters only if clearly needed and for the shortest duration.
Driving: May cause dizziness, drowsiness, or blurred vision. Patients should not drive or operate machinery until they know how the medication affects them.
| Anticoagulants (Warfarin, Acenocoumarol) | Increased risk of bleeding due to platelet inhibition and protein binding displacement. | Major |
| Other NSAIDs (Aspirin, Ibuprofen, Diclofenac) | Increased risk of GI toxicity (ulcers, bleeding) with no added therapeutic benefit. | Major |
| ACE Inhibitors (Ramipril, Enalapril) / ARBs (Losartan) | Reduced antihypertensive effect; risk of worsened renal function. | Moderate |
| Diuretics (Furosemide, Hydrochlorothiazide) | Reduced diuretic and antihypertensive efficacy; risk of nephrotoxicity. | Moderate |
| Lithium | Increased lithium levels and risk of toxicity due to reduced renal clearance. | Major |
| Methotrexate | Increased methotrexate levels and risk of hematologic toxicity. | Major |
| Corticosteroids (Prednisolone) | Markedly increased risk of GI ulceration and bleeding. | Major |
| Selective Serotonin Reuptake Inhibitors (SSRIs) e.g., Fluoxetine | Increased risk of upper GI bleeding. | Moderate |
| Antiplatelets (Clopidogrel) | Increased risk of GI bleeding. | Moderate |
| Cyclosporine | Increased risk of nephrotoxicity. | Major |
Same composition (Drotaverine (80mg) + Mefenamic Acid (250mg)), different brands: